EazyMed - Company finances
|
EUR
|
2020
From: 2020-07-23
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|
|
Financial data
|
||||||
| Sales revenue | 297,357 | 1,859,561 | 1,470,752 | 1,599,752 | 1,854,408 | 2,141,877 |
| Profit before tax | 95,537 | 11,564 | 5,662 | 61,151 | 43,503 | 96,916 |
| Net profit | 90,760 | 9,874 | 4,825 | 51,885 | 35,772 | 81,312 |
| Equity | 93,260 | 103,134 | 107,959 | 159,844 | 195,616 | 276,928 |
| Liabilities | 55,128 | 68,244 | 63,932 | 32,916 | 54,368 | 121,368 |
| Non-current assets | 0 | 0 | 0 | 0 | 0 | 0 |
| Current assets | 148,388 | 171,378 | 171,891 | 192,760 | 249,984 | 398,296 |
| Total assets | 148,388 | 171,378 | 171,891 | 192,760 | 249,984 | 398,296 |
|
Taxes paid
|
||||||
| Social insurance contributions | - | - | - | 8,239 | 12,719 | 24,938 |
|
Financial indicators
|
||||||
| Revenue change y/y | - | +525.4% | -20.9% | +8.8% | +15.9% | +15.5% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 61.2% | 5.8% | 2.8% | 26.9% | 14.3% | 20.4% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 97.3% | 9.6% | 4.5% | 32.5% | 18.3% | 29.4% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 30.5% | 0.5% | 0.3% | 3.2% | 1.9% | 3.8% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 32.1% | 0.6% | 0.4% | 3.8% | 2.3% | 4.5% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.6 | 0.7 | 0.6 | 0.2 | 0.3 | 0.4 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 106,199 | 398,475 | 320,894 | 355,500 | 353,221 | 276,371 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
EazyMed - Social security debts
The company had no debts to Sodra
EazyMed - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2025-05-06 | 2025-05-12 | 0.6 |
| 2025-05-01 | 2025-05-05 | 154.4 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
EazyMed, UAB (code 305593486) is a Private Limited Liability Company operating in the wholesale of pharmaceutical and medical goods. In 2025, the company generated revenue of €2.14M, up 15.5% year on year and 33.9% over two years. Net profit rose to €81.3K, compared with €35.8K in 2024 and €51.9K in 2023, while the profit margin improved to 3.8% from 1.9% a year earlier. The three-year trend shows steady revenue growth, a dip in profitability in 2024, and a stronger recovery in 2025. At the end of 2025, total assets reached €398.3K, supported by equity of €276.9K and liabilities of €121.4K. The equity ratio stood at 69.5%, with debt-to-equity at 0.44, indicating a comparatively solid capital structure. Efficiency indicators were also strong, with asset turnover at 5.38x, ROE at 29.4% and ROA at 20.4%. Revenue per employee was €306.0K, and profit per employee was €11.6K.